Nextgen Healthcare (NASDAQ:NXGN) had its price objective boosted by analysts at Cantor Fitzgerald from $12.00 to $13.00 in a report released on Friday, BenzingaRatingsTable reports. The firm currently has a “neutral” rating on the stock. Cantor Fitzgerald’s target price points to a potential downside of 11.08% from the stock’s previous close.

Other research analysts have also recently issued reports about the company. Piper Sandler lifted their price objective on Nextgen Healthcare from $17.00 to $23.00 and gave the company an “overweight” rating in a report on Friday. SVB Leerink started coverage on Nextgen Healthcare in a report on Monday, April 13th. They set a “market perform” rating and a $12.00 price objective for the company. Deutsche Bank cut their price objective on Nextgen Healthcare from $12.00 to $9.00 and set a “hold” rating for the company in a report on Tuesday, June 2nd. Royal Bank of Canada assumed coverage on Nextgen Healthcare in a report on Monday, April 20th. They set a “sector perform” rating and a $11.00 price objective for the company. Finally, Jefferies Financial Group cut their price target on Nextgen Healthcare from $14.00 to $11.50 and set a “hold” rating for the company in a report on Wednesday, April 22nd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. Nextgen Healthcare currently has an average rating of “Hold” and a consensus target price of $12.46.

NXGN opened at $14.62 on Friday. Nextgen Healthcare has a fifty-two week low of $5.10 and a fifty-two week high of $18.49. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.82 and a quick ratio of 1.82. The firm’s fifty day moving average price is $10.96 and its two-hundred day moving average price is $11.42. The company has a market capitalization of $975.34 million, a P/E ratio of 162.44, a P/E/G ratio of 5.85 and a beta of 0.99.

Nextgen Healthcare (NASDAQ:NXGN) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.17. The firm had revenue of $130.88 million for the quarter, compared to the consensus estimate of $115.11 million. Nextgen Healthcare had a net margin of 1.01% and a return on equity of 10.64%. On average, equities research analysts expect that Nextgen Healthcare will post 0.42 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of NXGN. UBS Group AG grew its position in shares of Nextgen Healthcare by 62.5% during the 4th quarter. UBS Group AG now owns 73,931 shares of the company’s stock worth $1,188,000 after buying an additional 28,427 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Nextgen Healthcare by 14.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 306,615 shares of the company’s stock worth $4,927,000 after buying an additional 39,172 shares during the period. UBS Asset Management Americas Inc. grew its position in shares of Nextgen Healthcare by 26.8% during the 4th quarter. UBS Asset Management Americas Inc. now owns 40,826 shares of the company’s stock worth $656,000 after buying an additional 8,636 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Nextgen Healthcare during the 4th quarter worth about $310,000. Finally, Man Group plc acquired a new position in shares of Nextgen Healthcare during the 4th quarter worth about $249,000. Institutional investors own 73.22% of the company’s stock.

About Nextgen Healthcare

NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.

Further Reading: Current Ratio

Analyst Recommendations for Nextgen Healthcare (NASDAQ:NXGN)

Receive News & Ratings for Nextgen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nextgen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.